Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-08-01), Biotest AG's 9-Day RSI is 46.17.
The industry rank for Biotest AG's 9-Day RSI or its related term are showing as below:
HAM:BIO's 9-Day RSI is not ranked
in the Biotechnology industry.
Industry Median: 41.82
vs HAM:BIO: 46.17
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Biotest AG 9-Day RSI Related Terms
HAM:BIO vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, Biotest AG's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotest AG 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biotest AG's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Biotest AG's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotest AG (HAM:BIO) has a 9-Day RSI of 46.17 as of Aug. 01, 2026.
Is Biotest AG's 9-Day RSI too high?
Biotest AG's current 9-Day RSI is 46.17. The Biotechnology industry median 9-Day RSI is 41.82. Biotest AG's value of 46.17 is 10.4% above this industry median. Overall, Biotest AG has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Biotest AG's 9-Day RSI compare to VRTX and REGN?
Biotest AG's 9-Day RSI of 46.17 can be compared against companies in the Biotechnology industry. The industry median 9-Day RSI is 41.82. Biotest AG's value of 46.17 is 10.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 41.82, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biotest AG's current 9-Day RSI of 46.17 is 10.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 41.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biotest AG's current 9-Day RSI is 46.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotest AG stock overvalued right now?
Biotest AG (HAM:BIO) has a current 9-Day RSI of 46.17. The current 9-Day RSI is 46.17 and 10.4% above the Biotechnology industry median of 41.82. Biotest AG's overall GF Score™ is 56/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Biotest AG (HAM:BIO), the current 9-Day RSI is 46.17 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The company covers preclinical and clinical development of the preparations, plasma collection, production, as well as marketing and sales.
56GF Score
Get the complete analysis for HAM:BIO
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BIO has been successfully added to your 
